Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 5/20 | 0.37 |
| ▸ | TTK | P33981 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.36 |
| ▸ | WNT1 | P04628 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 5/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | GAK | O14976 | 1/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | FECH | P22830 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5385856 | 0.99 | MAP3K5 (0.37) | MAP3K5TTKDYRK1AWNT1MAPK8 | |
| SCHEMBL5377040 | 0.99 | MAP3K5 (0.38) | MAP3K5TTKDYRK1AWNT1MAPK8 | |
| SCHEMBL5388476 | 0.96 | MAP3K5 (0.38) | MAP3K5TTKDYRK1AWNT1MAPK8 | |
| SCHEMBL5394533 | 0.86 | WNT1 (0.44) | DYRK1AWNT1PIM1LRRK2MAP4K4 | |
| SCHEMBL5383009 | 0.83 | WNT1 (0.40) | DYRK1AWNT1PIM1MAP4K4GSK3B | |
| SCHEMBL5383058 | 0.83 | TTK (0.38) | MAP3K5TTKDYRK1AWNT1MAPK8 | |
| SCHEMBL5380929 | 0.80 | PIM1 (0.43) | MAP3K5TTKDYRK1AWNT1PIM1 | |
| SCHEMBL5373940 | 0.79 | SSTR2 (0.34) | MAP3K5TTKDYRK1AWNT1MAPK8 | |
| SCHEMBL5378103 | 0.79 | MKNK1 (0.44) | MAP3K5TTKDYRK1AMAPK8PIM1 | |
| SCHEMBL5372630 | 0.79 | TTK (0.40) | MAP3K5TTKMAPK8LRRK2CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791831-A4 | METHODS OF TREATING DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES | SIGNAL PHARM LLC (US) | 2009-07-08 | — | — | EP | claimed |
| EP-1791831-A2 | METHODS OF TREATING DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES | Signal Pharmaceuticals LLC (US) | 2007-06-06 | — | — | EP | claimed |
| WO-2005051308-A2 | METHODS OF TREATING DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | claimed |
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-20050107386-A1 | Methods of treating diseases and disorders by targeting multiple kinases | NARLA RAMA KRISHNA (US) | 2005-05-19 | — | — | US | claimed |
| EP-1791831-A4 | METHODS OF TREATING DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES | SIGNAL PHARM LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1791831-A2 | METHODS OF TREATING DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES | Signal Pharmaceuticals LLC (US) | 2007-06-06 | — | — | EP | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| WO-2005051308-A2 | METHODS OF TREATING DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SINGNAL PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050107386-A1 | Methods of treating diseases and disorders by targeting multiple kinases | NARLA RAMA KRISHNA (US) | 2005-05-19 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | MAP3K5 7/4885TTK 1198/4885DYRK1A 1188/4885 |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAP3K5 6/4885TTK 476/4885DYRK1A 784/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | MAP3K5 2520/4885TTK 2139/4885DYRK1A 1932/4885 |
| US-20050107386-A1 | Methods of treating diseases and disorders by targeting multiple kinases | MAP3K20, MAP3K2, MAP3K1 | MAP3K5 7/4885TTK 29/4885DYRK1A 621/4885 |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAP3K5 6/4885TTK 464/4885DYRK1A 726/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAP3K5 6/4885TTK 476/4885DYRK1A 784/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | MAP3K5 32/4885TTK 714/4885DYRK1A 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.